LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Inicio・Lista de Acciones・Ardelyx Inc

Ardelyx Inc

Cerrado

Sector Salud

5.6 -2.61

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

5.57

Máximo

5.61

Métricas clave
By Trading Economics
Ingresos	-33M -27M
Ventas	12M 46M
BPA	-0.11
Margen de beneficio	-57.619
Empleados	267
EBITDA	-30M -22M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+92.68 upside

Dividendos
By Dow Jones
Próximas Ganancias	29 oct 2024

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	-7.7M 1.4B
Apertura anterior	8.21
Cierre anterior	5.6

Noticias sobre sentimiento de mercado

By Acuity

96%

339 / 365 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

5.485 / 6.3 Soporte y Resistencia

Ardelyx Inc Gráfico

Noticias Relacionadas

18 oct 2023, 12:15 UTC

Principales Movimientos del Mercado

Ardelyx Shares Rally Premarket on FDA Approval of Xphozah

Comparación entre iguales

Cambio de precio

Ardelyx Inc Esperado

Precio Objetivo

By TipRanks

92.68% repunte

Estimación a 12 meses

Media 10.79 USD 92.68%

Máximo 12.5 USD

Mínimo 7 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ardelyx Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

7 ratings

Comprar

Mantener

Vender

De acuerdo con 7 analistas que ofrecen calificaciones bursátiles a para Ardelyx Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

5.485 / 6.3Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Sentimiento

By Acuity

339 / 365 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Ardelyx Inc

Ardelyx, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of medicines to improve treatment for people with kidney and cardiorenal diseases. The Company's product pipeline includes Tenapanor, IBSRELA, RDX013 Program, and RDX020 Program. The Tenapanor is a medicine for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor for the control of serum phosphorus has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). RDX013 Program is a small molecule potassium secretagogue program for the potential treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis. It has a discovery program targeting the inhibition of intestinal bicarbonate exchange for the treatment of metabolic acidosis.